Table 1.
The ‘Integrated Care Pathway (ICP)’ framework for patient monitoring.
Table 2.
Total number of SbV doses received by each of the 67 patients.
Table 3.
Reasons for treatment suspensions and omissions.
Figure 1.
Box-and-whisker plot of the lymphocyte counts of patients plotted against duration of treatment with sodium stibogluconate (SbV).
The group median (squares) fell significantly from its baseline by the first subsequent measurement, four days after initiating treatment (p<0.001). It then plateaued, with no further significant change. Outliers are depicted by circles, extremes are depicted by hashes.
Figure 2.
Box-and-whisker plot of the platelet counts of patients plotted against duration of treatment with sodium stibogluconate (SbV).
The group median (squares) fell significantly from its baseline by the first subsequent measurement, four days after initiating treatment (p<0.001). It then plateaued, with no further significant change. Outliers are depicted by circles, extremes are depicted by hashes.
Figure 3.
Box-and-whisker plot of serum alanine transaminase concentrations against duration of treatment with sodium stibogluconate (SbV).
The group median (squares) rose significantly by day 10 after initiation of treatment (p<0.001). Outliers are depicted by circles, extremes are depicted by hashes.
Figure 4.
Percentage of patients reporting side-effects on each day of treatment with sodium stibogluconate (SbV).